Corporate Overview Corporate Overview March 2026 March 19, 2026 Publications ZB-168 potently inhibits thymic stromal lymphopoietin mediated inflammation (#WAC23-0179) World Allergy Congress (WAC) December 2, 2023 Phase 1 Clinical Trial Evaluating the Pharmacokinetics and Pharmacodynamics of a Novel IL-17A and BAFF Dual Antagonist in Sjogren’s Syndrome June 13, 2024
ZB-168 potently inhibits thymic stromal lymphopoietin mediated inflammation (#WAC23-0179) World Allergy Congress (WAC) December 2, 2023
Phase 1 Clinical Trial Evaluating the Pharmacokinetics and Pharmacodynamics of a Novel IL-17A and BAFF Dual Antagonist in Sjogren’s Syndrome June 13, 2024